Use of complement inhibitors to treat ocular diseases
AssigneeGenentech, Inc.
InventorsSek Chung Fung, Zhengbin Yao
Life of this patent
Estimating the term…
Abstract
The present invention relates to the treatment of ocular diseases and conditions by administering a complement pathway inhibitor, particularly an alternative pathway inhibitor Ocular diseases include age-related macular degeneration, diabetic retinopathy, and ocular angiogenesis. One embodiment comprises the administration of an anti-Factor D antibody in the form of a whole antibody, a Fab fragment or a single domain antibody. Other complement component inhibitors that may be useful in the present method include Factor H or inhibitors that block the action of properdin, factor B, factor Ba, factor Bb, C2, C2a, C3a, C5, C5a, C5b, C6, C7, C8, C9, or C5b-9.
Claims29
-27. (canceled)
A method for preventing or ameliorating an ocular disease that involves complement activation, comprising administering an effective amount of a complement inhibitor to a subject in need thereof.
A method of preventing or ameliorating an ocular disease that involves complement activation, comprising administering an siRNA specific for a complement pathway protein to a subject in need thereof.
A method of preventing or ameliorating an ocular disease that involves complement activation, comprising administering a nucleic acid encoding a complement inhibitor to a subject in need thereof.
Dependencies are inferred from the claim text.